Syschem (India) Ltd
Incorporated in 1993, Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.
- Market Cap ₹ 245 Cr.
- Current Price ₹ 61.5
- High / Low ₹ 73.9 / 33.4
- Stock P/E 71.7
- Book Value ₹ 6.30
- Dividend Yield 0.00 %
- ROCE 39.0 %
- ROE 31.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Stock is trading at 9.96 times its book value
- The company has delivered a poor sales growth of 11.3% over past five years.
- Company has a low return on equity of -9.02% over last 3 years.
- Debtor days have increased from 62.0 to 135 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11 | 16 | 18 | 11 | 4 | 13 | 67 | 93 | 77 | 68 | 59 | 114 | 173 | |
9 | 12 | 14 | 14 | 5 | 12 | 63 | 89 | 77 | 73 | 58 | 105 | 165 | |
Operating Profit | 2 | 4 | 4 | -3 | -1 | 0 | 3 | 4 | -0 | -5 | 1 | 9 | 8 |
OPM % | 14% | 24% | 22% | -23% | -24% | 0% | 5% | 4% | -0% | -7% | 1% | 8% | 5% |
0 | 0 | 1 | 0 | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 0 | 0 | |
Interest | 0 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
Profit before tax | 1 | 1 | 1 | -5 | -3 | -2 | 1 | 2 | -2 | -7 | -2 | 6 | 5 |
Tax % | 44% | 29% | 21% | 26% | 27% | 30% | 43% | 50% | 16% | 24% | 22% | 27% | |
0 | 1 | 1 | -4 | -2 | -1 | 0 | 1 | -2 | -6 | -2 | 5 | 3 | |
EPS in Rs | 0.17 | 0.49 | 0.30 | -1.94 | -1.13 | -0.75 | 0.17 | 0.32 | -0.79 | -2.07 | -0.59 | 1.13 | 0.86 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 22% |
5 Years: | 11% |
3 Years: | 14% |
TTM: | 104% |
Compounded Profit Growth | |
---|---|
10 Years: | 17% |
5 Years: | 59% |
3 Years: | 65% |
TTM: | -48% |
Stock Price CAGR | |
---|---|
10 Years: | 22% |
5 Years: | 50% |
3 Years: | 110% |
1 Year: | 66% |
Return on Equity | |
---|---|
10 Years: | -10% |
5 Years: | -7% |
3 Years: | -9% |
Last Year: | 32% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 19 | 19 | 22 | 23 | 32 | 32 |
Reserves | -4 | -3 | -2 | -6 | -8 | -10 | -9 | -8 | -10 | -16 | -17 | -10 | -7 |
Preference Capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | |
16 | 30 | 31 | 27 | 26 | 21 | 19 | 15 | 16 | 15 | 2 | 2 | 2 | |
3 | 4 | 10 | 14 | 13 | 17 | 31 | 37 | 37 | 56 | 52 | 69 | 58 | |
Total Liabilities | 31 | 48 | 55 | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 84 |
8 | 29 | 36 | 34 | 32 | 30 | 29 | 27 | 28 | 30 | 32 | 31 | 33 | |
CWIP | 14 | 4 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
10 | 14 | 18 | 16 | 15 | 14 | 28 | 35 | 34 | 46 | 28 | 62 | 51 | |
Total Assets | 31 | 48 | 55 | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 84 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0 | 4 | 4 | 1 | 0 | 6 | 0 | -2 | 3 | 4 | 1 | -8 | |
-14 | -13 | -3 | 0 | 0 | 0 | 0 | 2 | -4 | -4 | -1 | 9 | |
15 | 10 | -1 | -2 | -1 | -7 | -0 | -0 | -0 | -0 | -0 | -0 | |
Net Cash Flow | -0 | 1 | 0 | -1 | 0 | -0 | 0 | 0 | -0 | -0 | 0 | 1 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 128 | 115 | 143 | 187 | 272 | 124 | 47 | 21 | 47 | 31 | 21 | 135 |
Inventory Days | 107 | 214 | 280 | 228 | 868 | 182 | 80 | 104 | 110 | 199 | 152 | 61 |
Days Payable | 56 | 56 | 183 | 290 | 870 | 424 | 151 | 131 | 175 | 221 | 186 | 158 |
Cash Conversion Cycle | 180 | 273 | 240 | 124 | 271 | -119 | -24 | -7 | -19 | 9 | -14 | 38 |
Working Capital Days | 143 | 108 | 120 | 72 | 92 | -173 | -23 | -12 | -24 | 13 | -15 | 48 |
ROCE % | 4% | 8% | 8% | -11% | -8% | -6% | 3% | 8% | -8% | -29% | -13% | 39% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 18 Apr
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 17 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Apr
- Compliance:- Statement Of Deviation Or Variation For The Quarter Ended 31St March,2024 13 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Apr - Compliance certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for 31 March 2024.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2004
from bse
Product Profile:[1]
API/ Intermediates:
a) Amoxycillin Tri Hydrate
b) Ampicillin Tri Hydrate
c) Cloxacillin Sodium
d) Dicloxacillin Sodium
e) Flucloxacillin Sodium (For export only)
f) Cephalexin
g) Cefixime
h) Cefadroxil
i) Distillation of Specialty Solvents –
DMF, Acetonitrile, Ethyl Acetate and THF